Ultime notizie per Processa Pharma (NASDAQ:PCSA) Azioni

Processa Pharma

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals Inc

Rezolve AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) shares are trading higher Thursday after the company announced a strategic partnership with Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) to enhance global retail innovations <a href="https://www.benzinga.com/news/24/09/41032594/whats-going-on-with-rezolve-ai-limited-today">using AI-powered commerce solutions.</a>
What To Know: Rezolve AI and Microsoft have formed a collaboration to provide advanced digital engagement capabilities to retailers. Rezolve AI's Brain Suite—which includes Brain Commerce, Brain Checkout, and Brain Assistant—will be hosted on Microsoft Azure and available through the Azure Marketplace.
The partnership includes extensive Go-to-Market (GTM) and co-sell support from Microsoft for five years. This includes marketing, sales support through Microsoft&#8217;s 35,000 incentivized sellers, and technical assistance from the Microsoft AI Cloud Partner Program.
What Else: Rezolve AI&#8217;s Brain Suite aims to address common eCommerce challenges such as reducing cart abandonment and improving customer engagement with AI capabilities available in 95 languages. The solutions are designed to enhance operational efficiency and provide a quick return on investment (ROI).
RZLV And MSFT Price Action: Rezolve shares were up by 29.7% at $8.52 and Microsoft shares were up by 0.01% at $417.09 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga pro.</a>
See Also:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41166018/medicare-drug-price-negotiation-program-gets-final-guidance-for-second-cycle-1-5b-savings-expecte">Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected</a></li>
</ul>
Image via Unsplash.

News

Movers

MSFT

RZLV

Rezolve AI Shares Surge On Microsoft Partnership Announcement: What You Need To Know

Biotech

Global

General

GILD

Gilead Donates Remdesivir For Emergency Use In Response To Marburg Virus Disease In Rwanda; Says It Will Donate Approximately 5,000 Vials Of Remdesivir To Rwanda Medical Supply

Rosenblatt analyst Mike Genovese maintains Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) with a Buy and maintains $45 price target.

Price Target

Analyst Ratings

CALX

Rosenblatt Maintains Buy on Calix, Maintains $45 Price Target

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) mining stocks CleanSpark Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) and Riot Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) are seeing increased attention Thursday after the companies released <a href="https://www.benzinga.com/pressreleases/24/10/n41163693/cleanspark-releases-september-2024-bitcoin-mining-update">mining updates for September</a>.
What&#8217;s Going On With CLSK: CleanSpark said it mined 493 Bitcoin in September, up from 478 in August. The company has now mined a total of 5,079 Bitcoin year-to-date, bringing its total&nbsp;Bitcoin&nbsp;holdings up to 8,049 as of Sept. 30.
CleanSpark sold 2.5&nbsp;bitcoin last month at an average price of approximately&nbsp;$58,287&nbsp;per&nbsp;coin. The company had an average hashrate of 23.4 EH/s for the month, resulting in an average of 16.43&nbsp;Bitcoin&nbsp;mined daily. CleanSpark noted that it had a peak hashrate of 27.6 EH/s in September before Hurricane Helene impacted its operations at the end of the month.
CleanSpark noted that it experienced no material damage to any site infrastructure and is not aware of any material losses related to its mining servers. As of&nbsp;Oct. 2, all but 45 MW of power had been restored to the company&#8217;s sites. The remaining 45 MW is expected to be restored &#8220;in the coming days.&#8221;
&#8220;Our expansion efforts have not slowed down, and we are actively racking miners at newly acquired sites and at our existing facilities as part of our fleet upgrade plan,&#8221; said Zach Bradford, CEO of CleanSpark.
Through these efforts, we expect to reach 30 EH/s during&nbsp;October 2024. Looking ahead to fiscal year 2025, we are positioned to rapidly achieve our forecasted growth to 50 EH/s and beyond. We look forward to providing further updates on 2025 in the coming weeks.&#8221;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41150059/bitcoin-ethereum-dogecoin-continue-downward-trend-range-deviation-or-bearish-retest-wonder">Bitcoin, Ethereum, Dogecoin Continue Downward Trend: &#8216;Range Deviation Or Bearish Retest?,&#8217; Wonders Technical Trader</a>
What&#8217;s Going On With RIOT: Riot Platforms also announced its mining metrics for September on Thursday. Riot said it mined 412 Bitcoin last month, up 28% from 322 in August. 
&#8220;This increase in production was driven by an increase in average operating hash rate across all our facilities and was achieved despite periodic curtailment that took place through our participation in the final month of ERCOT&#8217;s Four Coincident Peak (4CP) program for 2024, whereby we paused mining operations during periods of high demand on the grid,&#8221; said Jason Les, CEO of Riot. 
Riot had an average operational hashrate of 19.5 EH/s during the month, up from 14.5 EH/s in August. 
&#8220;We are excited about the results we are seeing from our growing hash rate and operational improvements, which are directly translating into increased production and improved efficiency. Following the completion of our third 100 MW building, Building B1, at our Corsicana Facility during the month, we achieved a total deployed hash rate capacity of 28.2 EH/s,&#8221; Les said.
CLSK, RIOT Price Action: At the time of publication, <a href="http://benzinga.com/quote/clsk">CleanSpark shares</a> were down 1.93% at $8.62 and <a href="http://benzinga.com/quote/riot">Riot shares</a> were down 0.28% at $7.28, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

CLSK

RIOT

What's Going On With Bitcoin Mining Stocks CleanSpark, Riot Platforms?

In the current market session, Estee Lauder Cos Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) share price is at $95.22, after a 1.96% decrease. Over the past month, the stock went up by 5.76%, but over the past year, it actually decreased by 34.42%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2024/1727968597_0.png" alt="Past Year Chart" />

<h3>Estee Lauder Cos P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 50.26 in the Personal Products industry, Estee Lauder Cos Inc. has a higher P/E ratio of 89.93. Shareholders might be inclined to think that Estee Lauder Cos Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1727968597_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

A Look Into Estee Lauder Cos Inc's Price Over Earnings

Bilibili Inc &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) shares are trading lower by 9.44% to $26.86 Thursday morning, pulling back following a 90% surge over the past month, which was fueled by mounting optimism around China&#8217;s aggressive <a href="https://www.benzinga.com/news/24/10/41165162/china-stocks-are-cooling-off-thursday-whats-going-on">stimulus measures</a> aimed at reviving its sluggish economy.
Shares of major Chinese tech companies, including Alibaba, Baidu and JD.com, also experienced declines as concerns over escalating geopolitical tensions in the Middle East dampened investor sentiment.
What To Know: Bilibili, a popular video-sharing platform with a focus on anime, gaming and youth-centric content, has become one of China's leading online entertainment companies. It caters primarily to Gen Z and millennial users, offering a mix of user-generated content, live streaming, and mobile games. 
Despite this strong market position and a recent uptick in its stock price, driven by China&#8217;s recent stimulus actions, the company remains vulnerable to broader market movements and external risks.
Chinese markets reacted negatively on Thursday, as investors grew cautious amid fears of a potentially expanding conflict in the Middle East. The resulting uncertainty, especially regarding energy prices and global supply chains, has created concerns for emerging markets like China.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41166146/would-bitcoin-drop-if-a-war-in-the-middle-east-breaks-out-yes-but-theres-a-catch">Would Bitcoin Drop If A War In The Middle East Breaks Out? Yes, But There&#8217;s A Catch</a>
An elevated oil risk premium could hurt China's economic outlook, as it is heavily reliant on imported energy. In turn, this may affect consumer confidence and spending, which are crucial for platforms like Bilibili, where advertising revenue and in-app spending are sensitive to broader economic conditions.
What Else: Additionally, while China's recently announced measures—such as mortgage refinancing and fiscal spending to stimulate growth—have provided a short-term boost to tech stocks, the sustainability of this recovery remains a question mark. 
Bilibili, like other Chinese tech companies, has been navigating a challenging landscape over the past year, facing headwinds from China's regulatory tightening on technology and entertainment sectors, as well as weakened advertising demand.
Read Also: <a href="https://www.benzinga.com/news/24/10/41159016/port-strike-enters-day-3-economist-warns-of-meaningful-impact-if-standoff-prolongs-food-beverages-li">Port Strike Enters Day 3: Economist Warns Of &#8216;Meaningful&#8217; Impact If Standoff Prolongs, Food &amp; Beverages Likely First To Feel The Pinch</a>
<h2 class="wp-block-heading">How To Buy BILI Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Bilibili&#8217;s case, it is in the Communication Services sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, BILI has a 52-week high of $31.77 and a 52-week low of $8.80.

BILI

Why Bilibili Stock Is Volatile Today

WIIM

Vistra shares are trading higher after RBC Capital maintained an Outperform rating on the stock and raised its price target from $105 to $141.

<a href="https://www.benzinga.com/personal-finance/24/09/40922368/excuse-me-you-want-to-check-my-credit-nba-legend-shaq-shares-he-felt-disrespected-when-trying-to">Shaquille O'Neal</a> no longer owns his massive Orlando mansion as of 2024, but the story behind it reveals a lot about the NBA legend's personal life.&nbsp;
During a 2018 appearance on The Ellen DeGeneres Show, Shaquille O'Neal shared a surprising fact about his 76,000-square-foot mansion – he only used two rooms. "The kitchen because I like to eat, and the bedroom because I like to sleep," he joked, offering a glimpse into his surprisingly simple lifestyle despite the enormous size of his home.
Don't Miss:
<ul>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
<li>Beating the market through ethical real estate investing' — t<a href="https://www.benzinga.com/money/invest-with-roots">his platform aims to give tenants equity in the homes they live in while scoring 17.17% average annual returns for investors – here&#8217;s how to join with just $100</a></li>
</ul>
Curious, DeGeneres asked, "What about the living room or a den?" Shaq shook his head. "No, I never go to the theater, never go to the gym," he admitted, leaving much of the house untouched.
DeGeneres then asked Shaq how many bathrooms were in his house, to which he casually replied, "I think 15." DeGeneres joked, "You know you're supposed to flush the toilets and run the water once a week so it doesn't smell." Shaq laughed, admitting, "I never knew that." DeGeneres playfully suggested that his housekeeper should be taking care of it, to which Shaq responded with a grin, "I don't have a housekeeper; I clean it myself." The audience cheered before he quickly added, "Just playing," drawing more laughter.
Trending: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.
The exchange showed Shaq's ability to balance humor with a glimpse into his life, revealing that even with all the luxury, he keeps things lighthearted and down-to-earth.
The mansion in Windermere, Florida, was packed with extravagant features, including a 17-car showroom, a cigar room, a wine cellar, a custom theater, and even a Miami Heat-themed basketball court. However, Shaq admitted during a podcast interview that the house didn't always bring him happiness. He opened up about <a href="https://www.benzinga.com/personal-finance/24/09/40943843/we-aint-rich-im-rich-nba-legend-shaq-says-his-daughters-and-sons-dont-get-equal-treatment-my-boy">feeling lonely in the mansion</a> after his divorce from his ex-wife, Shaunie Nelson. "I built this house for them," he shared. "But after the divorce, I would come home to a 76,000-square-foot house with nobody there but me. That was the worst part."
Trending: Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a>
Shaq purchased the property back in 1993 for around $3.95 million. After nearly three decades, it proved difficult to sell. The mansion was initially listed at $28 million in 2018, but after struggling to find a buyer, he had to lower the price multiple times. By January 2019, the price dropped to $22 million, and later to $16.5 million after making some updates and switching real estate agents.
Even with the updates and price reductions, Shaq's mansion remained on the market for a while. In January 2021, he thought he had a buyer, but the deal fell through. Finally, in October 2021, the mansion was sold to a dentist for $11 million – far below the original asking price. Shaq later admitted, "I'm actually sick that I sold it," but didn't dwell much on the loss.
While it's <a href="https://www.benzinga.com/real-estate/24/09/40836966/do-you-want-to-look-inside-no-ill-take-it-shaq-bought-a-house-on-the-spot-because-it-was-right-acros">no longer his residence</a>, the story of Shaq's mansion shows that even <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">celebrities with vast fortunes</a> and gigantic homes can feel the weight of isolation. Despite the luxury, sometimes you need two rooms to live in – and the people who matter most to share it with.
Read Next:
<ul>
<li>This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a></li>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's an opportunity to invest at $1,000 for only $0.50/share today.</a></li>
</ul>

Real Estate

NBA Legend Shaq Only Used 2 Rooms In His 76,000 Sq Ft. Mansion: 'The Kitchen Because I Like To Eat And The Bedroom Because I Like To Sleep'

<a href="https://www.texasattorneygeneral.gov/news/releases/attorney-general-ken-paxton-sues-big-pharma-drug-manufacturers-and-pharmacy-benefit-managers">https://www.texasattorneygeneral.gov/news/releases/attorney-general-ken-paxton-sues-big-pharma-drug-manufacturers-and-pharmacy-benefit-managers</a>
Texas Attorney General Ken Paxton sued major insulin manufacturers and pharmacy benefit managers (&quot;PBMs&quot;)&mdash;including Eli Lilly, Express Scripts, CVS Pharmacy, and others&mdash;over a conspiracy to increase prices of insulin.&nbsp;
Through this conspiracy, the manufacturers artificially and willingly raised the prices of insulin then paid a significant, undisclosed portion back to the PBMs as a quid pro quo for inclusion in the PBMs&#39; standard offerings. The PBMs then granted preferred status to the manufacturer whose drug has the highest list price while excluding lower priced drugs. These synthetic insulin drugs, which today cost the manufacturers less than $2 to produce and were originally priced at $20 when released in the late 1990s, now range between $300 and $700. In the last decade alone, the manufacturers who are defendants in the lawsuit have increased the prices of their insulins up to 1,000%. Attorney General Paxton is suing because the insulin pricing scheme violates the Texas Deceptive Trade Practices Act, constitutes unjust enrichment, and represents an unlawful civil conspiracy.
&quot;This is a disturbing conspiracy by which pharmaceutical companies were intentionally and artificially inflating the price of insulin. Big Pharma insulin manufacturers and PBMs worked together to take advantage of diabetes patients and drive prices as high as they could,&quot; said Attorney General Paxton. &quot;These companies acted illegally and unethically to enrich themselves, and we will hold them accountable.&quot;
According to the complaint, &quot;While the PBM Defendants represent that they perform their services on behalf of their clients (including Texas payors) and diabetics to lower drug prices, increase access to affordable drugs, and promote diabetic health, these representations are false. Rather, the PBM Defendants have worked in coordination with the Manufacturer Defendants to distort the market for diabetic treatments to their benefit at the expense of Texas diabetics and payors.&quot;
Liston &amp; Deas, David Nutt &amp; Associates, the Cicala Law Firm, and Foreman Watkins Krutz are serving as outside counsel.

Legal

Texas Attor­ney Gen­er­al Ken Pax­ton Sues Big Phar­ma Drug Man­u­fac­tur­ers And Phar­ma­cy Ben­e­fit Man­agers For Con­spir­a­cy

Equinox Gold Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQX#NASDAQ">EQX</a>) shares are trading lower by 5.3% to $5.84 during Thursday&#8217;s session after the company announced it has issued <a href="https://www.benzinga.com/pressreleases/24/10/g41159996/equinox-gold-announces-convertible-note-conversion-and-bought-deal-secondary-offering">24,761,905 shares</a>.
What To Know: Equinox Gold has issued 24.76 million common shares to Ninety Fourth Investment Company, an affiliate of MDC Industry Holding, following the conversion of a US$130 million convertible note. 
These shares will now be sold in a secondary offering, led by BMO Capital Markets, at a price of US$5.65 per share, generating gross proceeds of approximately US$140 million for Ninety Fourth.
Equinox Gold says the company will not receive any proceeds from this sale, but the conversion reduces the company&#8217;s debt and boosts liquidity. MDC originally acquired the note in 2019 and will retain a second US$130 million convertible note with a maturity date in 2025. The offering is expected to close by October 9.
Read Also: <a href="https://www.benzinga.com/news/24/10/41165162/china-stocks-are-cooling-off-thursday-whats-going-on">China Stocks Are Cooling Off Thursday: What&#8217;s Going On?</a>
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, EQX has a 52-week high of $6.50 and a 52-week low of $3.95.

Why Equinox Gold (EQX) Stock Is Falling

Cantor Fitzgerald analyst Louise Chen reiterates Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) with a Overweight and maintains $155 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Merck & Co, Maintains $155 Price Target

MicroCloud Hologram Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) shares are falling Thursday after shareholders approved a 1-for-20<a href="https://www.benzinga.com/pressreleases/24/10/n41151788/microcloud-hologram-inc-announces-results-of-its-2024-annual-general-meeting-of-the-shareholders"> reverse stock split</a>.
The Details:
MicroCloud Hologram announced on Wednesday that shareholders had approved the reverse stock split which is intended to regain compliance with the minimum bid price Nasdaq listing requirement. The stock will begin trading on a split-adjusted basis on Oct. 9, 2024.&nbsp;
The reverse split will reduce the number of MicroCloud&#8217;s outstanding Class A ordinary shares from 410,883,973 shares to 20,544,198 shares.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/24/10/41152629/what-happened-with-accenture-stock-today">What Happened With Accenture Stock Today?</a>
According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, MicroCloud shares are trading below the stock&#8217;s 50-day moving average of 36 cents and are approaching its 52-week low of 20 cents.&nbsp;
<h3 class="wp-block-heading">How To Buy HOLO Stock:</h3>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in MicroCloud Hologram's case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
HOLO Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, MicroCloud Hologram shares are down 19.4% at 27 cents at the time of publication Thursday.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41122476/whats-going-on-with-microstrategy-stock">What&#8217;s Going On With MicroStrategy Stock?</a></li>
</ul>
Image: Vilius Kukanauskas from Pixabay

Penny Stocks

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

What's Going On With MicroCloud Hologram Stock?

BlackSky Technology Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) shares are trading higher Thursday after the company was awarded a five-year contract to monitor <a href="https://www.benzinga.com/pressreleases/24/10/b41162786/blacksky-wins-five-year-nga-luno-a-contract-valued-up-to-290-million-to-monitor-global-economic-ac">global economic activity and military capabilities</a>.
What Happened: The U.S. National Geospatial-Intelligence Agency (NGA)&nbsp;awarded BlackSky Technology&nbsp;a multi-award indefinite-delivery, indefinite-quantity contract worth up to&nbsp;$290 million over five years. 
Under the contract, BlackSky will monitor global economic and environmental activity and military capability using satellite imagery and <a href="http://benzinga.com/topic/ai">AI</a>-driven change-detection analytics.
The company expects to provide analytical services that detect and identify objects of interest such as aircraft, ships, vehicles and shipping containers. BlackSky will also detect changes to the Earth such as deforestation, construction, mining, flooding and other phenomena that contribute to climate change or wildfires.
&#8220;The Luno A contract validates demand for BlackSky&#8217;s commercial real-time, AI-driven dynamic monitoring services at massive scale,&#8221; said Brian O&#8217;Toole, CEO of BlackSky Technology.
&#8220;BlackSky&#8217;s first-of-its-kind space-based intelligence system delivers answers to our customers&#8217; most pressing questions at industry-leading speed and economics.&#8221;
Don&#8217;t Miss: <a href="https://www.benzinga.com/general/space/24/09/41013092/boeing-vs-spacex-will-stumbles-in-union-negotiations-space-travel-weaken-aerospace-giants-standing-">Boeing Vs. SpaceX: Will Union Talk Stumbles, Space Travel Weaken Aerospace Giant&#8217;s Standing Against Elon Musk&#8217;s Company?</a>
Luno A is the follow-on contract to the NGA&#8217;s&nbsp;$60 million&nbsp;Economic Indicator Monitoring contract which was originally&nbsp;awarded in 2021. The contract will also support the development of new and emerging products, data and services such as novel AI solutions. 
&#8220;BlackSky&#8217;s commitment to automation across our entire architecture has had the cumulative effect of generating new, foundational machine learning tools for the U.S. government that will advance the key areas of focus for Luno A,&#8221;&nbsp;O&#8217;Toole added.
BKSY Price Action: <a href="http://benzinga.com/quote/bksy">BlackSky shares</a> were up 6.61% at $5.32 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo:&nbsp;<a href="https://pixabay.com/users/piro4d-2707530/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=4242493">PIRO</a>&nbsp;from&nbsp;<a href="https://pixabay.com//?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=4242493">Pixabay</a>.

SPACE

BlackSky Technology Inc. Class A Common Stock

BKSY

BlackSky Technology Stock Is Soaring Thursday: What's Going On?

Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares are up this Thursday. Here&#8217;s <a href="https://www.benzinga.com/markets/equities/24/10/41141540/palantir-technologies-partners-with-edgescale-ai-to-operationalize-ai-in-manufacturing-and-utili">what you need to know.</a>
What To Know: A Barron&#8217;s report noted that Palantir co-founder and chairman Peter Thiel has completed selling the <a href="https://www.benzinga.com/news/24/10/41145602/palantir-stock-is-moving-higher-wednesday-whats-going-on">maximum number of shares</a> under a trading plan he initiated in May. Thiel sold 12.412 million shares at an average price of $36.85 per share from September 27 through October 1 via Rivendell 7 LLC, leaving the entity with approximately 34.26 million shares. This sale was completed ahead of the December 31, 2025 deadline.
Palantir also announced a multi-year strategic partnership with Edgescale AI to enhance artificial intelligence (AI) operations in manufacturing, utilities and other industrial sectors. According to Brian Mengwasser, co-founder and CEO of Edgescale AI, the objective is to simplify the deployment of AI capabilities, integrating Palantir's software on Edgescale's Live Edge platform to provide direct access to operational data and automate physical processes.
What Else: Additionally, Palantir was among the top-20 <a href="https://www.benzinga.com/top-stories/24/10/41150827/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-september-2024-where-do-tesla-nvidia-apple">most searched tickers on Benzinga Pro </a>last month, indicating high investor interest.
PLTR Price Action: Palantir shares were up by 3.03% at $38.63 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="560" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03095501/PLTR-1024x560.png" alt="" class="wp-image-578738" style="width:567px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03095501/PLTR-1024x560.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03095501/PLTR-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03095501/PLTR-768x420.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03095501/PLTR.png 1045w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also:
<ul>
<li><a href="https://www.benzinga.com/24/10/41165282/nike-gears-up-to-get-back-in-shape-with-a-new-leader">Nike Gears Up To Get Back In Shape With A New Leader</a></li>
</ul>
Image via Shutterstock.

PLTR

What's Going On With Palantir Stock Today?

<a href="https://thebearcave.substack.com/p/problems-at-roblox-rblx-4" title="https://thebearcave.substack.com/p/problems-at-roblox-rblx-4">https://thebearcave.substack.com/p/problems-at-roblox-rblx-4</a>

Short Sellers

Trading Ideas

RBLX

Watching Roblox; The Bear Cave Issues Fourth Report On Co Titled "Problems at Roblox (RBLX) #4"

California's recent emergency regulations targeting hemp-derived products are making waves across the cannabis industry. Governor <a href="https://www.benzinga.com/markets/cannabis/24/09/41012794/gov-newsoms-hemp-ban-goes-into-effect-consequences-for-industry-investors-patients">Gavin Newsom's emergency order </a>has sparked concerns, with businesses questioning the sweeping restrictions and their impact on the state and national markets.
Brandon Harshbarger, president of Cheech &amp; Chong Global Holdings, weighed in on the implications of these changes for the industry. Speaking ahead of his appearance at the upcoming <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference,</a> Harshbarger detailed how the restrictions are already causing fallout across California's cannabis and hemp markets.
<h3 class="wp-block-heading">Restricting Hemp: Who Wins and Who Loses?</h3>
Harshbarger, whose company operates in both the recreational cannabis and hemp markets in California, emphasized the disconnect between the state's portrayal of hemp products and the reality. "We've been more vocal than some, but the reality is there are some very large rec operators that are also producing excellent hemp-derived products in California along with many other states," he explained.
The emergency order not only affects producers but also ripples through the supply chain, harming retailers and wholesalers that had previously operated within the framework of AB45, a law allowing hemp-derived THC products under specific guidelines. &#8220;What the state isn't recognizing is that AB45 was crafted with very specific requirements for hemp producers to follow,&#8221; Harshbarger pointed out, noting that many of the products targeted by the ban complied with these regulations.
<h3 class="wp-block-heading">A Multi-Billion Dollar Loss?</h3>
One of the most striking figures Harshbarger provided was the potential financial hit. Using Minnesota as a comparison, he highlighted that hemp-derived THC beverages alone had generated nearly $200 million in sales in just over a year. "If you extrapolate population and store counts, it becomes easy to see that just the hemp-derived THC drink category is worth more than a billion dollars in sales a year to the State of California,&#8221; he added.
This, combined with the broader restrictions on hemp-derived products, means the potential economic impact could be far-reaching, affecting not just businesses but also employment and state tax revenues.
<h3 class="wp-block-heading">A Call for Unified Action</h3>
Harshbarger sees a silver lining in the situation, suggesting that the restrictions could galvanize recreational cannabis and hemp operators to work together for policy reform. "My hope is that this event is going to galvanize both the rec and hemp operators in California so we can craft policy that makes sense for greater access and healthier companies to combat the illicit market," he said.
As the debate over hemp and cannabis regulations continues, it's clear that California's decisions will have national implications. The current market, as Harshbarger stated, "is untenable," and these emergency measures may push the industry to reevaluate its approach to cannabis and hemp alike.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41164499/californias-hemp-ban-likely-wont-be-the-last-will-it-push-consumers-back-to-licensed-operators">California&#8217;s Hemp Ban &#8216;Likely Won&#8217;t Be The Last&#8217;: Will It Push Consumers Back To Licensed Operators?</a></li>
</ul>
Photo: Courtesy of Kyrylo Vasyliev via Shutterstock

Cannabis

Events

Exclusives

Interview

Will California's Hemp Ban Cost The State Billions? 'Just The Drink Category Is Worth Over A Billion' Says Expert

Albany International shares are trading lower after the company cut its FY24 guidance.

VRNA

Verona Pharma shares are trading higher after Wells Fargo initiated coverage on the stock with an Overweight rating and announced a price target of $50.

Over the past 24 hours, Arbitrum's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ARB</a>) price has fallen 3.71% to $0.53. This continues its negative trend over the past week where it has experienced a 16.0% loss, moving from $0.63 to its current price. 
The chart below compares the price movement and volatility for Arbitrum over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1727967823_0.png" alt="price_chart" />
The trading volume for the coin has climbed 9.0% over the past week, moving opposite, directionally, with the overall circulating supply of the coin, which has decreased 0.07%. This brings the circulating supply to 3.62 billion, which makes up an estimated 36.17% of its max supply of 10.00 billion. According to our data, the current market cap ranking for ARB is #50 at $1.90 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1727967823_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$ARB

Cryptocurrency Arbitrum Down More Than 3% Within 24 hours

<a href="https://www.globenewswire.com/Tracker?data=cdrZ-B8uy93P-Qc3Jvwh1oIFI3gAebHEioKE4CNgGBXA8yMZTrbMLsQvOBAanVWSsDMTrxsVkiarfmZOmqniEwjmX-zvQK8R9J6c2-II7xV2MteReYg9WkEdEqxxpLTN">Alignment Health Plan</a>, an award-winning Medicare Advantage plan from Alignment Health, today announced it is expanding access to high-quality health care and services for its members in Clark and Washoe counties through a new agreement with <a href="https://www.globenewswire.com/Tracker?data=I1do1Z9aCFxxLvAQ1c7xkLzL7VAnB1vgpLuHIwPEjDmjv45WrjR5TpkR93zWjIHU44oalNPk2BZWKqr1pcI7p591w4E7Lwqhodqo0vgn3H4=">Intermountain Health</a>. Effective Jan. 1, 2025, the agreement will provide Alignment's Nevada members access to more than 65&nbsp;clinic locations in the Silver State, 35 of which are award-winning senior primary care clinics.

ALHC

Alignment Health Plan Expands Provider Network With Intermountain Health, Enhancing Care Access In Nevada, Effective Jan. 1, 2025

Processa Pharmaceuticals appoints CFO

Processa Pharmaceuticals (PCSA) has provided an update. Processa Pharmaceuticals, Inc. has appointed seasoned industry expert Russell Skibsted as t...

Processa Pharmaceuticals Welcomes New CFO Russell Skibsted

FDA approves Processa Phase 2 study for NGC-Cap, stock rallies 46%

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Processa Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/pcsa-stock-quote/">PCSA</a>) stock is rising higher on Tuesday after the company <a href="https://finance.yahoo.com/news/processa-pharmaceuticals-announces-fda-clearance-120000203.html">posted an update</a> from the Food and Drug Administration (FDA).



The FDA has cleared Processa Pharmaceuticals for its Phase 2 clinical trial Next Generation Capecitabine (NGC-Cap). This is the company&rsquo;s lead product candidate and is designed to treat patients with advanced or metastatic breast cancer.



With this approval, Processa Pharmaceuticals is able to move forward with a clinical trial of NGC-Cap. The company says that it expect to start enrolling patients in this study this quarter.



David Young, president of research and development at Processa Pharmaceuticals, said this about NGC-Cap.




&ldquo;We previously demonstrated in our Phase 1b study that NGC-Cap is more potent than monotherapy capecitabine, providing up to 5-10 times more 5-fluorouracil exposure to cancer cells. This greater exposure resulted in a greater efficacy, with a safety profile better or similar to existing monotherapy with capecitabine.&rdquo;




<h2>PCSA Stock Movement Today</h2>



With all of this comes heavy trading of PCSA stock today. That has more than 51 million shares changing hands as of this writing. This is a massive surge compared to the company&rsquo;s daily average trading volume of about 90,000 shares.



PCSA stock is up 29.4% as of Tuesday morning.



Investors seeking out even more of the most recent stock market stories are going to want to stick around!



We are offering up insight into all of the hottest stock market news that investors need to know about on Tuesday! A few examples include what&rsquo;s happening with shares of Tesla&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/tsla-stock-quote/">TSLA</a>), Delta&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/dal-stock-quote/">DAL</a>) and SoFi&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sofi-stock-quote/">SOFI</a>) stock today. All of that news is ready to go at the links below!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/tsla-stock-drops-as-tesla-recalls-1-8-million-evs-over-hood-issue/">TSLA Stock Drops as Tesla Recalls 1.8 Million EVs Over Hood Issue</a></li>



<li><a href="https://investorplace.com/2024/07/dal-stock-delta-wants-crowdstrike-to-pay-up-for-flight-delays-caused-by-outage/">DAL Stock: Delta Wants CrowdStrike to Pay Up for Flight Delays Caused by Outage</a></li>



<li><a href="https://investorplace.com/2024/07/sofi-stock-sofi-just-raised-its-profit-guidance-again-whats-going-on/">SOFI Stock: SoFi Just Raised Its Profit Guidance Again. What&rsquo;s Going On?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-processa-pharmaceuticals-pcsa-stock-up-29-today/">Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
2U&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/twou-stock-quote/">TWOU</a>) stock is still rallying higher as a bankruptcy filing has introduced an immense amount of volatility to the online education platform company&rsquo;s shares.



Today&rsquo;s movement has TWOU stock rallying 15.5% as of Tuesday morning. That comes with more than 31 million shares changing hands. For the record, its daily average trading volume is about 2.5 million shares.



The rally today <a href="https://investorplace.com/2024/07/2u-twou-stock-pops-more-than-100-despite-bankruptcy-filing/">follows a surge yesterday</a> that saw the stock jump as more than 100% higher during normal trading hours. It is worth noting that these rallies come after the stock suffered a roughly 60% drop when news of its bankruptcy broke.



<h2>What&rsquo;s Next for 2U Stock?</h2>



2U is using this bankruptcy to <a href="https://investorplace.com/2024/07/twou-stock-alert-2u-plunges-on-ch-11-bankruptcy-filing/">restructure its debt</a> via deals with lenders. This has the company continuing operations throughout the process. It expects to exit bankruptcy by the end of September.



It&rsquo;s also unclear how this bankruptcy filing will affect TWOU stock. While the company is only using it for restructuring, it could cause problems for its listing on the Nasdaq Exchange.



Also, all of this volatility makes TWOU stock a bit of a risky investment. Traders will want to keep that in mind before taking a stake in the company.



Investors will want to stick around for more of the most recent stock market news!



We have all of the hottest stock market stories that traders need to know about on Tuesday! That includes warnings of a potential market crash, why Processa Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/pcsa-stock-quote/">PCSA</a>) stock is up today and more. All of this info is ready to go at the links below!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/a-potential-stock-market-crash-trigger-looms-on-july-31/">A Potential Stock Market Crash Trigger Looms on July 31</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-processa-pharmaceuticals-pcsa-stock-up-29-today/">Why Is Processa Pharmaceuticals (PCSA) Stock Up 29% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/tsla-stock-drops-as-tesla-recalls-1-8-million-evs-over-hood-issue/">TSLA Stock Drops as Tesla Recalls 1.8 Million EVs Over Hood Issue</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/2u-twou-stock-continues-to-surge-in-bankruptcy-rally/">2U (TWOU) Stock Continues to Surge in Bankruptcy Rally</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

2U (TWOU) Stock Continues to Surge in Bankruptcy Rally

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Processa Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/pcsa-stock-quote/">PCSA</a>) just reported results for the second quarter of 2024.<ul><li>Processa Pharma reported earnings per share of -$1.01. This was below the analyst estimate for EPS of -98 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/pcsa-stock-earnings-processa-pharma-for-q2-of-2024/">PCSA Stock Earnings: Processa Pharma Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PCSA Stock Earnings: Processa Pharma Misses EPS for Q2 2024

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Processa Pharmaceuticals (PCSA – Research Report), H...

Analysts Are Bullish on Top Healthcare Stocks: Processa Pharmaceuticals (PCSA), Healthequity (HQY)

Processa Pharmaceuticals reports GAAP EPS of -$1.01

Processa stock rallies 35% post-market on Phase 2 study update

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Processa Pharmaceuticals (PCSA – Research Report), retaining the price target o...

Buy Rating Affirmed for Processa Pharmaceuticals Amidst Promising Phase 2 Trial for NGC-Cap

PCSA

PSNL

SOFI

TSLA

TWOU

Press Releases

Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

Comments

Processa Pharma

Notizie

Ultime notizie per Processa Pharma (NASDAQ:PCSA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO